An interventional study of 3 weeks wearing of study device instead of their current wearing solution in Presbyopia, sponsored by Morrow Eyewear. Recruiting at 3 sites in 2 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Morrow Eyewear · Not applicable, Interventional, and Supportive care
Presbyopia is a common age-related condition where the eye loses its ability to focus on nearby objects, typically from around age 45.
The standard correction is progressive addition lenses (PALs), but these have limitations: narrow viewing zones, peripheral distortion, and the need for unnatural head movements, which can affect comfort and safety.
Morrow has developed an electronically adjustable progressive lens (Morrow eProgressive) that dynamically adapts its optical zones.
This CE-marked device is already commercially available. This study compares its functional performance against standard PALs.
Approximately 50 adults (≥45 years) will participate at three sites (Belgium and Italy). Each participant wears both glasses types for three weeks each, in random order.
Researchers will measure head and eye movements during reading tasks, stair descent performance, and visual comfort via a questionnaire. Participants will also indicate their overall lens preference.
Traditional PALs are characterized by fixed optical corridors bordered by lateral astigmatism. This spatial restriction imposes a significant physiological and biomechanical burden on the wearer during dynamic visual tasks. When executing lateral gaze shifts, such as shifting from the end of a line of text to the beginning of the next during reading, or scanning the ground during locomotion, wearers must either tolerate peripheral blur or employ compensatory head movements. The Morrow eProgressive utilizes active electronic focal adaptation to provide an expanded, uncompromised visual field, theoretically mitigating these optical limitations and restoring natural oculomotor patterns.
A key challenge in presbyopic clinical trials is the high degree of inter-individual variability. Factors such as individual neuro-visual adaptation speed and prior spectacle history vary widely between patients. To eliminate these significant confounding variables, this investigation utilizes a randomized, open-label, crossover design. By allowing each participant to serve as their own internal control across balanced 3-week wear periods, the study isolates the direct optical impact of the lens technology from confounding patient specific characteristics, vastly increasing the statistical validity of the intra-subject comparisons.
This study optimizes clinical efficiency by employing a dual-layered endpoint strategy:
330 studies on the registry are indexed under Presbyopia; 35 are open to participants now.
This study's planned enrollment of 50 is below the median of 60 across 271 interventional studies indexed under Presbyopia.
Browse Presbyopia studies →This is the only study on the registry with Morrow Eyewear as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
3 weeks wearing of study device instead of their current wearing solution
Procedure: 3 weeks wearing of study device instead of their current wearing solution
3 weeks wearing of study device instead of their current wearing solution
Procedure: 3 weeks wearing of study device instead of their current wearing solution
Instead of wearing their current solution for presbyopia, all participants can solely wear allocated spectacles during the duration of the trial for all day to day activities.
Reduction in head gain
Reduction in head gain: defined as the ratio of head yaw angle to total gaze angle, assessed during optotype reading across varying horizontal and vertical gaze angles, to evaluate the superiority of the Morrow eProgressive over the control Progressive Addition Lens (PAL) in facilitating more efficient gaze strategies and dynamic visual performance.
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean stair descent time
Stair Descent Performance: The change in mean stair descent time (measured in seconds) during a standardized stair descent test, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL).
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean cadence variability
Stair Descent Performance: The change in mean cadence variability (gait stability metric) during a standardized stair descent test, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL).
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Mean NAVQ-P score
Patient-Reported Visual Quality: change in the mean Near Visual Acuity Questionnaire Presbyopia (NAVQ-P) score, compared between the Morrow eProgressive and the control Progressive Addition Lens (PAL), reported on a scale from 0 to 3 with lower scores having a better outcome.
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Subjective Lens Preference for Vision
Subjective Lense Preference for Vision: the proportion of participants expressing an overall preference in terms of better vision for the Morrow eProgressive lens compared to the control Progressive Addition Lens (PAL), as evaluated by a post-wear Lens Preference Questionnaire, reported on a scale from 1 to 10 with higher scores having a better outcome.
Time frame: Comparing the 3-week wearing period at visit 4, with the 3-week wearing period at visit 3
Plan to share: No — This study will be registered in a public trial register (clinicaltrials.gov) prior to inclusion of the first subject. The content - including the participating Principal Investigators and Clinical Study Sites - will be updated throughout the conduct of the study. Results information from this study will be submitted to the public trial register. A study publication will be developed with the participating investigators at the end of the study.
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.